ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of ImageneBio (NASDAQ:IMA) from a sell rating to a strong sell rating in a report published on Sunday morning.

Separately, Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $26.50.

ImageneBio Stock Performance

Shares of IMA stock opened at $5.68 on Friday. The firm’s 50-day moving average is $5.61 and its 200-day moving average is $6.51. The stock has a market cap of $60.49 million, a price-to-earnings ratio of -0.98 and a beta of 0.73. ImageneBio has a 52-week low of $3.94 and a 52-week high of $18.00.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25). Sell-side analysts predict that ImageneBio will post -4.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IMA. Deep Track Capital LP acquired a new position in ImageneBio in the 3rd quarter valued at about $7,160,000. Blue Owl Capital Holdings LP acquired a new position in ImageneBio in the 3rd quarter valued at about $4,409,000. Atlas Venture Life Science Advisors LLC acquired a new position in ImageneBio in the 3rd quarter valued at about $3,079,000. Vanguard Group Inc. acquired a new position in ImageneBio in the 3rd quarter valued at about $1,902,000. Finally, BML Capital Management LLC acquired a new position in ImageneBio in the 3rd quarter valued at about $1,487,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.